How do venture capitalists spread risk by diversification within specialised life science portfolios? Online publication date: Mon, 03-Apr-2006
by Holger Patzelt, Dodo Zu Knyphausen-Aufseß, Ilona Arnoldt
International Journal of Technology Management (IJTM), Vol. 34, No. 1/2, 2006
Abstract: Venture Capitalists (VC) invest large amounts of money in risky start-up firms. In order to keep their investment risks low, they carefully select their portfolio companies and systematically spread risks portfolio companies are well studied, little is known about how VCs diversify their portfolios, in particular when dedicated to one industry. We introduce a framework for analysis of dedicated life science portfolios. By applying it to seven portfolios and drawing on additional interview data, we find that VCs invest more in risky drug development companies and less in medical technology, diagnostics and service/supply firms when their portfolio also contains non-life science firms. A higher portion of drug development firms correlate with more diversification within this sub-portfolio among different therapeutic markets and lead compound technologies. We conclude that specialisation within one industry on certain technologies or markets does not contribute to VCs' risk reduction.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Management (IJTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook